Contortrostatin

Drug Profile

Contortrostatin

Alternative Names: PB 2

Latest Information Update: 17 Nov 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Southern California
  • Developer Pivotal BioSciences; University of Southern California
  • Class Antiplatelets; Cytostatics; Disintegrins
  • Mechanism of Action Integrin inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours; Thrombosis

Most Recent Events

  • 14 Dec 2007 Preclinical development for Solid tumours is ongoing
  • 14 Dec 2007 Discontinued - Preclinical for Thrombosis in USA (IV)
  • 14 Jun 2004 Contortrostatin licensed to Pivotal BioSciences worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top